Nordic Pharma Announces European Launch of Lacrifill Canalicular Gel

Nordic Group, the parent company of Nordic Pharma, announced the European launch of Lacrifill, a novel therapy for the management of dry eye disease. Following CE mark approval in April 2025, Lacrifill is now available to healthcare professionals and patients across multiple European markets.

Lacrifill is a cross-linked hyaluronic acid gel designed to temporarily block tear drainage by physiologically occluding the canalicular system. By enhancing tear film preservation, the therapy helps maintain natural lubricating tears on the ocular surface, offering an individualised approach to dry eye management. The in-office procedure provides a complete fill of the canalicular system and delivers long-lasting effects for up to 6 months.

Dry eye disease is a highly prevalent condition, affecting up to 30% of the European population, and poses particular challenges for patients undergoing ocular surgical procedures. Pre-existing ocular surface disease in candidates for cataract or LASIK surgery can compromise surgical outcomes and negatively impact patient satisfaction.

“Achieving a stable ocular surface is a vital prerequisite for successful surgical outcomes,” said Professor José Benítez del Castillo of the Complutense University of Madrid, Spain. “The introduction of Lacrifill to the European market is a welcome development, providing us with a new tool for pre- and postoperative ocular surface health optimization and ensuring our patients have access to the latest advancements in ocular care.”

“The European launch of Lacrifill represents a significant milestone for Nordic Pharma. We are proud to bring this innovative dry eye therapy to patients and healthcare professionals across Europe, and we believe it will help many of those currently living with dry eye disease and become an important addition to dry eye management, particularly around ocular surgery," said Charlotte Phelps, CEO of Nordic Group.

Nordic Pharma will continue to work closely with the ophthalmology community across Europe to support the introduction of Lacrifill, including through medical education initiatives aimed at improving standards of ocular surface optimization.

Originally published online on Eyewire+.